No Data
Shionogi Announces Tender Offer to Acquire TORII Pharmaceutical
Shionogi Expands Pharmaceutical Capabilities With Strategic Acquisitions
Key points of interest in the PTS on the 7th = Kawasaki Kisen, Torii Pharmaceutical, HENNG, Mercari, JT, ETC.
▽ Kawasaki Kisen <9107.T>, the consolidated operating profit Financial Estimates for the fiscal year ending March 2026 is projected to be 105 billion yen (a 66% decrease compared to the previous period). ▽ Torii Pharmaceutical <4551.T> and Shionogi <4507.T> are conducting a tender offer (Buy). The purchase price is 6,350 yen. ▽ HENNGEE <4475.T> has increased its consolidated performance Financial Estimates for the fiscal year ending September 2025. The acquisition of new orders, including large projects, exceeded expectations. ▽ Mercari <4385.T>, cumulative total for the third quarter of the fiscal year ending June 2025 (from July 2024 to March 2025).
Shionogi: Extraordinary Report
Shionogi: Tender Offer Period Is From May 8 to June 18
Shionogi Pharmaceutical in Japan will acquire Torii Pharmaceutical for 150 billion yen.
According to reports, Japan's Shionogi Pharmaceutical Company plans to acquire Torii Pharmaceutical Company for approximately 150 billion yen (about 1.01 billion USD). Shionogi will acquire shares of Torii Pharmaceutical through a tender offer from Japan Tobacco Company and other Shareholders.
